Massive new registry aims to unlock secrets of biologic drugs

NCT ID NCT04784364

Recruiting now Knowledge-focused Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who responds best. The goal is to improve future treatment decisions, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this registry could help doctors better predict how patients will respond to biologic treatments, leading to more personalized care.
What could go wrong: This is an observational registry, not a treatment trial. It collects data only and does not test any new drug or therapy, so direct patient benefits are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma autoimmune disease immune system disorder inborn error of immunity Primary Immunodeficiency Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES IMMUNOLOGICAL DISEASE PRIMARY IMMUNE DEFICIENCY

Contacts and locations

Locations

Mount Sinai
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.